%0 Journal Article %A Luka C. Liebrand %A Samuel J. Natarajan %A Matthan W.A. Caan %A P. Rick Schuurman %A Pepijn van den Munckhof %A Bart de Kwaasteniet %A Judy Luigjes %A Isidoor O. Bergfeld %A Damiaan Denys %A Guido A. van Wingen %T Distance to white matter trajectories is associated with treatment response to internal capsule deep brain stimulation in treatment-resistant depression %D 2019 %R 10.1101/19008268 %J medRxiv %P 19008268 %X Objective Deep brain stimulation (DBS) is an innovative treatment for treatment-resistant depression. DBS is usually targeted at specific anatomical landmarks, with patients responding to DBS in approximately 50% of cases. Attention has recently shifted to white matter tracts to explain DBS response, with initial open-label trials targeting white matter tracts yielding much higher response rates (>70%).Methods We associated distance to individual white matter tracts around the stimulation target in the ventral anterior limb of the internal capsule to treatment response. We performed diffusion magnetic resonance tractography of the superolateral branch of the medial forebrain bundle and the anterior thalamic radiation in fourteen patients that participated in our randomized clinical trial. We combined the tract reconstructions with the postoperative images to identify the DBS leads and estimated the distance between tracts and leads, which we subsequently associated with treatment response.Results Stimulation closer to both tracts was significantly correlated to a larger symptom decrease (r=0.61, p=0.02), suggesting that stimulation more proximal to the tracts was beneficial. There was no difference in lead placement with respect to anatomical landmarks, which could mean that differences in treatment response were driven by individual differences in white matter anatomy.Conclusions Our results suggest that deep brain stimulation of the ventral anterior limb of the internal capsule could benefit from targeting white matter bundles. We recommend acquiring diffusion magnetic resonance data for each individual patient.Competing Interest StatementM.W.A. Caan is shareholder of Nico-lab BV. The remaining authors declare no competing financial interests.Funding StatementThis study was supported by an Innovation Impulse grant (#2015.011) from the Academic Medical Center and a ZonMw grant, nr. 171201008.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableWe are not allowed to share data, since complete anonymization is impossible and the data can be traced back to individual patients. %U https://www.medrxiv.org/content/medrxiv/early/2019/10/08/19008268.full.pdf